Welcome to our dedicated page for Prothena SEC filings (Ticker: PRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotechnology filing packed with clinical data tables and milestone accounting notes can feel daunting. Prothena’s SEC documents are no exception—trial updates, R&D burn rates, and partnership revenue estimates are buried across hundreds of pages. If you have ever searched for “Prothena SEC filings explained simply” or struggled to trace insider sales before a data readout, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries translate Prothena quarterly earnings report 10-Q filing details into clear language, flag key cash-runway metrics, and link every risk factor to its clinical program. Need “Prothena insider trading Form 4 transactions” or “Prothena executive stock transactions Form 4” alerts? We deliver them in real-time, alongside expert context. From a single dashboard you’ll also find the Prothena annual report 10-K simplified, “Prothena proxy statement executive compensation” tables highlighted, and each “Prothena 8-K material events explained” within minutes of hitting EDGAR.
Whether you monitor biologics pipeline milestones or compare quarter-over-quarter R&D expenses, our platform keeps every document at your fingertips:
- Real-time updates the moment Prothena Form 4 insider transactions hit the tape
- AI summaries that clarify immunotherapy terminology and clinical-stage accounting
- Side-by-side “Prothena earnings report filing analysis” for trend spotting
Form 144 Filing for Pinterest, Inc. (PINS) discloses a proposed insider sale by Benjamin Silbermann. The notice covers 102,083 Class A common shares, with an aggregate market value of $3,554,110. The seller intends to execute the transaction through Charles Schwab & Co. on or about 18 June 2025 on the NYSE. The amount equals roughly 0.02 % of the company’s 594,233,850 outstanding shares.
The filing also lists nine prior sales by the same insider during the past three months, totaling 1,129,187 shares and gross proceeds of approximately $36.99 million. The largest single block was 408,332 shares sold on 14 May 2025 for $13.54 million. All shares were originally acquired on 18 April 2019 as “Founders Shares” and are classified as a gift transfer for reporting purposes.
Rule 144 requires insiders to certify that they possess no undisclosed material adverse information at the time of filing. While the sale is relatively small versus total float, the cumulative volume of recent dispositions may draw investor attention to insider sentiment and potential stock-supply pressure.
FAQ
What is the current stock price of Prothena (PRTA)?
What is the market cap of Prothena (PRTA)?
What is Prothena Corporation Plc's core focus?
Which therapeutic areas are addressed by Prothena?
How does Prothena support its clinical development?
What distinguishes Prothena’s approach in the biotechnology sector?
What is the significance of the antibody-based therapeutics developed by Prothena?
Who are the intended beneficiaries of Prothena's products?
How does Prothena ensure reliability in its research?
